Key result
In TRAP-stimulated platelets, activation of CD36 presentation by thapsigargin was higher in patients with type 2 diabetes compared to healthy donors.
Cross-Sectional (n=61)
Diabetic platelets exhibit altered calcium mobilization dynamics, being more vulnerable to cytosolic calcium releasers and more resistant to calcium blockers compared to healthy platelets.
Answers are grounded in this paper and cite their sources.
Heightened diabetic platelet reactivity to calcium releasers may elevate thrombotic risk; hypothesis-generating for targeted therapies, not yet practice-changing.
UNLABELLED: Thrombospondin (TSP), which is secreted from alpha-granules of activated platelets, binds to its surface receptor (CD36) in the presence of Ca2+. OBJECTIVES: We monitored how the modulation of intraplatelet Ca2+ affects TSP binding to CD36 on platelets from healthy donors and patients with type 2 diabetes mellitus. We also aimed to verify whether the impaired Ca2+ mobilisation in diabetes influences TSP binding upon the pharmacological modulation of calcium transport. METHODS: Whole blood cytometry was used to monitor TSP release/binding and CD36 presentation in platelets from 28 type 2 patients and 33 healthy donors. RESULTS: No significant changes in TSP and CD36 levels were revealed between the groups in circulating platelets and TRAP-, collagen- or thrombin-activated platelets. In healthy donors, 1 microM thapsigargin (TG) elevated the TRAP-activated TSP binding (by up to 50%, p<0.001), 5 mM EGTA reversed the effect (by up to 85%, p<0.001), and overcame the effect of TG when used together. Less profoundly expressed effects occurred in the NIDDM group. In both groups TG increased the presentation of CD36 in TRAP-stimulated platelets (p<0.05), whereas EGTA lowered the TRAP-stimulated increase in CD36 (p<0.001). The inhibition of CD36 by EGTA was stronger in healthy volunteers (41% vs. 32%, respectively, p<0.05), whereas the activation by TG was higher in the NIDDM group (11% vs. 27%, p<0.05). When acting together the suppressive effects of EGTA on TG-dependent Ca2+ mobilisation were much attenuated in diabetic subjects (p<0.05). CONCLUSION: Both the release of TSP and CD36 presentation are under the influence of agents modulating intracellular Ca2+. Diabetic platelets seem more vulnerable to the releasers of cytosolic [Ca2+] and more resistant to the blockers of cytosolic [Ca2+] mobilisation.
No takes yet. Share an insight, caveat, or question.
Więcławska et al. (2001) conducted a cross-sectional in Type 2 diabetes mellitus (n=61). Type 2 diabetes mellitus vs. Healthy donors was evaluated on Activation of CD36 presentation by thapsigargin in TRAP-stimulated platelets (p=<0.05). In TRAP-stimulated platelets, activation of CD36 presentation by thapsigargin was higher in patients with type 2 diabetes compared to healthy donors.
Synapse has enriched 10 related papers. Consider them for comparative context: